生物化疗对肾癌转移病灶远期疗效的临床观察.pdfVIP

2007 年第 34 巷第 18 期 中@肿竭I隐患 .1041. 生物化疗对肾癌转移病灶远期疗效的临床观察 摘要 目的-探讨生物化拧时肾癌转移病虫土的远期疗安t ，方法特 63 j如l 肾造明细胞癌本后患者分为 2 姐:生物 化舟姐 30 例，术后 2 周行 IFN-α+IL-2+5-FU 生物化拧;对照纽 33 剖，本后未进行生物化，于。结果·生物化咛组中拉 生存时间为 22 个月，高于对照姐(9 个月);且生存曲线也高于对照扭，经Log 咀nk 检验，10.01 ;且生楠化拧期间，转 移址总旋解率为 33.39毛，药物不良反应。- I 度。锚论:Rohson 1Vb 期病理类型为肾造明细胞菇患者本后配合生物化 拧能提高生存丰，可且使部分特移病住缓解，且葫物不良反应能叶是，值得临库推广。 关键词生物化好 肾癌透明细胞癌特移拧盘 Clinical Observation of Long-term Efficacy of Biochemotherapy in the Treatment of Metastatic Lesions of Renal Cell Carcinoma Li Changfu Yan Qiuzhe Kong Xiangbo et al Departrrænt 0/ Urology. The TlmWr Hospital 0/Harbin Medical University, Harbin Abstract Obj四tive: To investigate long-term eflIcacy.of biochemotherapy for melastatic lesions of renal cell carcinoma. Metb田18: Sixty -three patients with renal carcinoma who received radical 肥肉rectomy and had pathologic ihdicatiollS of clear-cell carcinoma were divided into two groups. TI盯­ ty patients in the treatment group were treated with biochemo生herapy， consisting of a regimen of IFN-α and IL-2 plus 5-FU 2 weeks after the radical nephrectomy. 币1e other 33 patients in the control group received no biochemotherapy after the radical operation. Resul臼:币1e 皿edian surviva1 time for patients in the trea1menl group was 22 monlhs , whích w出 much longer than the 9 months seen in the conlrol group. The survival cu凹e for the biochemotherapy group was higher 也皿 that of the control group (P 0.01). The ovemll remission rate for patients with metastatic lesions was 63 .3%, and the adverse side effect. ranged from degree 0 10 1. Conclusion: The 8urvival rate can be increased in patients with clear-c